Celdara Medical (United States)

Recent papers from Celdara Medical (United States)

1. Pre-clinical Development of a Novel CAR-T Therapy Targeting TIM-1 for Treating Solid Tumors 2309293The Journal of Immunology · 2026
2. Programmable regulatory T cell platform for control of neuroinflammatory diseases 2310203The Journal of Immunology · 2026
3. Using chimeric antigen receptor (CAR) T Cells to autoimmune systemic sclerosis (SSc) 4232The Journal of Immunology · 2025
4. Anti-CD206 CAR T Cell Treatment Restores Fibrosis-Induced Loss of Dermal White Adipose Tissue2025
5. Sclerotic GVHD and Scleroderma Share Dysregulated Gene Expression that is Ameliorated by EREG Therapeutic AntibodyBlood · 2025
6. Human CAR Tregs Targeting SOD1 and Expressing BDNF Reduce Inflammation and Delay Disease in G93A hSOD1-NSG MiceCells · 2025
7. Human Islet Amyloid Polypeptide (hIAPP) Protofibril‐Specific Antibodies for Detection and Treatment of Type 2 DiabetesAdvanced Science · 2022
8. Self‐Assembled Human Skin Equivalents Model Macrophage Activation of Cutaneous Fibrogenesis in Systemic SclerosisArthritis & Rheumatology · 2022
9. Targeting of intragraft reactive oxygen species by APP-103, a novel polymer product, mitigates ischemia/reperfusion injury and promotes the survival of renal transplantsAmerican Journal of Transplantation · 2020
10. Exploiting natural killer group 2D receptors for CAR T-cell therapyFuture Oncology · 2017
11. Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell–Treated MiceThe Journal of Immunology · 2016